SMS Lifesciences India

What SMS Lifesciences India does

SMS Lifesciences India Limited (recently rebranded Haleos Labs Limited) is a Hyderabad-based, publicly listed pharmaceutical manufacturer specializing in active pharmaceutical ingredients (APIs) and intermediates. The company traces to a 1990 single-facility, single-product operation within the SMS Group and now operates three manufacturing sites: Khazipally Unit-I (Japan PMDA-qualified, COFEPRIS-inspected, 7 production blocks, ~450 KL reactor volume, Ranitidine HCl at 2,400 MTA), Jeedimetla Unit-IV (intermediate supply to innovators and other units, ~51.25 KL), and Mahi Drugs Private Limited (wholly-owned US FDA-inspected Visakhapatnam subsidiary). It also runs a DSIR-recognized R&D center for process, analytical and scale-up research.

The portfolio covers 25+ APIs across 14 therapeutic classes, including anti-ulcer (Ranitidine HCl, Famotidine, Cimetidine), anti-convulsant (Fosphenytoin Sodium, Tiagabine, Pregabalin), anti-emetic (Domperidone, Fosaprepitant Dimeglumine, Aprepitant), anti-depressant (Trazodone HCl, Mirtazapine, Bupropion), and niche segments such as anesthesia, ophthalmic, obesity and hair-loss, supported by USDMFs, CEPs, and ASMF filings. A proprietary green-chemistry platform is claimed to deliver 100% atom efficiency via Methyl Mercaptan gas conversion at industry scale. The company demerged from SMS Pharmaceuticals in 2017, acquired Mahi Drugs in 2018, and was rebranded Haleos Labs in August 2025.

The business model is B2B contract manufacturing and direct API/intermediate supply to global pharmaceutical companies, patent holders and Indian formulators across US, EU, Japan, Canada and Mexico, executed under CRAMS engagements and collaborative manufacturing with leased production blocks. Pricing is quote-based and not publicly disclosed. Regulatory credibility is anchored in successive US FDA inspections (2018, 2022 at Unit-I; January 2025 at Mahi Drugs) plus PMDA, COFEPRIS, ANVISA and WHO-GMP certifications; industry recognition includes the India Pharma Bulk Drug Company of the Year Award 2020 and the Pharmexcil Outstanding Export Performance Award 2018-19.

Name

SMS Lifesciences India

Legal name

SMS Lifesciences India Limited

Website

https://smslife.in

Company type

Public

Founded year

1990

Operating status

Operating

Headcount range

501–1,000 employees

Short description

SMS Lifesciences India (now Haleos Labs Limited) is a Hyderabad-based public pharmaceutical manufacturer producing 25+ APIs and intermediates across anti-ulcer, anti-convulsant, anti-emetic and other therapeutic classes for global pharma firms, patent holders and Indian formulators via three manufacturing sites and CRAMS engagements.

Ownership category

akta.pro rank

Product category

Pharmaceutical API Manufacturing

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical Preparation Manufacturing (325412), Scientific Research and Development Services (5417), Pharmaceutical and Medicine Manufacturing (32541)

SIC

Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Generic APIs & Intermediates (Active Ingredients) (HLAIABAG)

akta.pro secondary industries

Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC) (HLAGAHAM), Chiral / Asymmetric Synthesis & Complex Chemistry Services (HLAGAHAE)

Keywords

• Active Pharmaceutical Ingredients
• Pharmaceutical intermediates manufacturing
• Contract research manufacturing services
• API contract manufacturing
• Bulk drug production

Headquarters

HQ city

Hyderabad

HQ country

India

HQ region

Asia

Offices4 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Technology or R&D, Personnel, Infrastructure

Revenue model

1. API Manufacturing: Manufacturing and sale of Active Pharmaceutical Ingredients (APIs) including Ranitidine HCl, Famotidine, Sildenafil Citrate, and 20+ other products across therapeutic segments like Anti Ulcer, Anti Fungal, Anti Convulsant, Anti Depressant.
2. Intermediates Supply: Supply of pharmaceutical intermediates to patent holders in US & EU markets and to other SMS Lifesciences units. Jeedimetla UNIT-IV specifically supplies intermediates to innovators and other units.
3. Contract Manufacturing (CRAMS): Contract manufacturing of API and Intermediates offering competitive advantage to clients in late stage lifecycle of products. Includes exclusive manufacturing for clients and collaborative manufacturing arrangements with leased production blocks.
4. Contract Research: Contract research assignments for global customer base. R&D center delivers contract research modules to international clientele with expertise in process research, analytical research and scale-up.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Core offering

SMS Lifesciences manufactures Active Pharmaceutical Ingredients (APIs) and pharmaceutical intermediates, and offers Contract Research and Manufacturing Services (CRAMS) to global pharmaceutical companies. The company operates three multi-product manufacturing facilities with a DSIR-recognized R&D center, producing 25+ APIs across therapeutic segments (anti-ulcer, anti-convulsant, anti-depressant, anti-emetic, anti-hypertensive, anti-fungal, etc.) with regulatory approvals from US FDA, Japan PMDA, COFEPRIS, and WHO-GMP.

Product overview

SMS Lifesciences India is a pharmaceutical company offering a comprehensive portfolio of Active Pharmaceutical Ingredients (APIs), pharmaceutical intermediates, and Contract Research and Manufacturing Services (CRAMS). The company produces over 25 APIs across multiple therapeutic segments including Anti Ulcer (Ranitidine HCl, Famotidine, Cimetidine), Anti Convulsant (Fosphenytoin Sodium, Tiagabine HCl, Pregabalin), Anti Emetic (Domperidone, Fosaprepitant Dimeglumine, Aprepitant), Anti Depressant (Trazodone HCl, Mirtazapine, Bupropion HCl), Anti Hypertension (Nicardipine HCl), Anti Infective (Dapsone), Anti Fungal (Itraconazole), Anti Obesity (Sibutramine HCl), Anti Gout (Allopurinol), Anti Worm (Albendazole), Anesthesia (Ropivacaine HCl), and others (Minoxidil for Hair Loss, Brinzolamide and Naphazoline for Ophthalmic). The company operates manufacturing facilities including Khazipally UNIT-I (Japan PMDA qualified, COFEPRIS inspected) and Jeedimetla UNIT-IV, with a subsidiary Mahi Drugs Private Limited in Visakhapatnam. Their services include contract manufacturing, collaborative manufacturing, and custom synthesis through their DSIR-recognized R&D center.

Differentiator

Problem solved

Functional benefit

Products and services

• Ranitidine HCl (Form-2) USP / EP / IP
• Famotidine USP / EP / IP Anti Ulcer active pharmaceutical ingredient available in USP/EP/IP pharmacopeial standards with DMF available and CEP applied.
• Sildenafil Citrate USP / EP / IP Erectile Dysfunction active pharmaceutical ingredient with USDMF available and CEP available.
• Allopurinol USP / EP / IP Anti Gout active pharmaceutical ingredient with USDMF available and CEP available.
• Ropivacaine HCl USP / EP / IP Anesthesia active pharmaceutical ingredient with USDMF available and CEP available.
• Dapsone USP / EP / BP Anti Infective active pharmaceutical ingredient with USDMF available and CEP available.
• Sibutramine HCl USP Anti Obesity active pharmaceutical ingredient with DMF available.
• Itraconazole USP / EP Anti Fungal active pharmaceutical ingredient with DMF available.
• Fosphenytoin Sodium USP Anti Convulsant active pharmaceutical ingredient with USDMF available and ASMF available.
• Domperidone / Domperidone Maleate EP / IP Anti Emetic active pharmaceutical ingredient with DMF available and CEP applied.
• Tiagabine HCl USP Anti Convulsant active pharmaceutical ingredient with USDMF available.
• Albendazole USP / EP / IP Anti Worm active pharmaceutical ingredient with USDMF available and CEP applied.
• Fosaprepitant Dimeglumine Anti Emetic active pharmaceutical ingredient with USDMF available.
• Hydroxyzine HCl USP / EP / IP Anti Histamine active pharmaceutical ingredient with USDMF available and CEP applied.
• Trazodone HCl USP / EP / IP Anti Depressant active pharmaceutical ingredient with USDMF available and CEP applied.
• Nicardipine HCl USP / EP / IP Anti Hypertension active pharmaceutical ingredient with DMF available.
• Furosemide USP / EP / IP Diuretics active pharmaceutical ingredient with USDMF available and CEP applied.
• Cimetidine USP / EP / IP Anti Ulcer active pharmaceutical ingredient with USDMF available.
• Mirtazapine USP / EP / IP Anti Depressant active pharmaceutical ingredient with USDMF available.
• Pregabalin USP / EP / IP Anti Convulsant active pharmaceutical ingredient with DMF available.
• Minoxidil USP / EP / IP Hair Loss active pharmaceutical ingredient with USDMF available.
• Aprepitant USP / EP / IP Anti Emetic active pharmaceutical ingredient with USDMF available and CEP applied.
• Naphazoline HCl / Nitrate Ophthalmic active pharmaceutical ingredient with DMF available.
• Bupropion HCl USP / IP Anti Depressant active pharmaceutical ingredient with Tech Pack available.
• Brinzolamide USP / IP Ophthalmic active pharmaceutical ingredient with Tech Pack available.
• Pharmaceutical Intermediates Advanced and basic pharmaceutical intermediates including Ranitidine HCl Intermediates, Famotidine Intermediates, Rizatriptan Intermediates, Sildenafil Intermediates, Imatinib Intermediates, Itraconazole Intermediates, Domperidone Intermediates, Ropivacaine HCl Intermediates, and others; supplied to patent holders in US & EU markets and other SMS Lifesciences units.
• CRAMS (Contract Research and Manufacturing Services) Contract manufacturing of API and Intermediates (advanced and basic) offering competitive advantage to clients, including custom synthesis, process development, and mass manufacturing of customer's own discovery products. Targeted at pharmaceutical patent holders and innovators requiring late-stage lifecycle support.
• Collaborative Manufacturing Multipurpose production blocks available for lease period, with SMS Lifesciences providing production team, utilities, services, and access to documentation and QA/QC; serves clients requiring dedicated manufacturing capacity without owning facilities.

Quantifiable outcome

• Reduced Ranitidine production process from 7 stages to 4 stages
• +4 more outcomes

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Two partnerships are on record, tiered core.

• HRV GlobalcoreStrategic or Co-development PartnerCollaboration with HRV Global mentioned in corporate announcements. The nature and scope of this partnership appears to be related to business development or market expansion activities.
• Mahi Drugs Private LimitedcoreOthersSubsidiary company acquired by SMS Lifesciences in 2018. Located at Plot no 82 J N Pharma city, Visakhapatnam, Andhra Pradesh. The subsidiary completed US FDA inspection in January 2025. Mr. TVVSN Murthy serves as Director and Mr. TV Praveen serves as Managing Director of Mahi Drugs.

Scale indicators7 records

Recent moves11 records

Expansion highlights6 records

Broad incumbents

• Granules India: Indian manufacturer of APIs, intermediates and finished pharmaceutical formulations with US FDA facilities serving regulated generic customers. Comparable on API/intermediates manufacturing model and DMF-led US market access, with broader finished-dose capabilities.
• Aurobindo Pharma: Large Indian vertically-integrated generics and API manufacturer with extensive US FDA-approved facilities and global distribution. Overlaps with SMS on API/intermediates production and generic-pharma supply but operates at far greater scale across finished formulations as well.
• Dr. Reddy's Laboratories: Major Indian pharmaceutical company with deep API manufacturing history (and the heritage employer of SMS MD TVVSN Murthy at Cheminor Drugs Limited). Adjacent on Hyderabad footprint, API heritage, and regulated-market approvals, though vastly larger and finished-formulation-focused.
• Piramal Pharma Solutions: India-headquartered CDMO offering API manufacturing, drug substance and contract development to global innovator pharma. Comparable to SMS on the contract-manufacturing arm and innovator-customer GTM, but operates a much broader integrated services portfolio across multiple modalities.

Direct peers

• Divis Laboratories: Indian API and intermediates manufacturer based in Hyderabad with significant custom synthesis / CRAMS business, multi-site regulatory approvals (US FDA, EU, Japan), and global pharma customers. Directly comparable on manufacturing model, regulatory footprint, and Hyderabad operating base.
• Neuland Laboratories: Hyderabad-based API manufacturer focused on contract development & manufacturing (CDMO) and generic APIs with US FDA, EDQM, and PMDA certifications. Direct match on CRAMS + generic-API mix, therapeutic segment breadth, and regulatory matrix.
• Suven Life Sciences: Hyderabad-based pharma company with CRAMS, API, and specialty intermediates offerings to global innovator pharma. Comparable size range, same Hyderabad/Andhra-Pradesh operating footprint, and shared focus on late-stage lifecycle API manufacturing.
• Sai Life Sciences: India-headquartered CRAMS and contract research organization offering custom synthesis, process development, and API manufacturing for innovator pharma. Comparable on the innovator-facing CDMO arm that Unit-IV Jeedimetla targets, and on green-chemistry/process-R&D positioning.
• Aarti Industries: Indian specialty chemicals and intermediates manufacturer with API exposure, complex chemistry capabilities, and multi-site regulatory certifications. Comparable on intermediates/API manufacturing footprint, complex chemistry expertise (analogous to SMS's chiral/green-chemistry positioning), and export-oriented B2B model.
• Laurus Labs: Hyderabad-headquartered API and CRAMS player with US FDA-approved facilities supplying generic and innovator customers globally. Closely comparable to SMS on API + CRAMS dual model, therapeutic breadth, and regulated-market access.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Compliance8 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about SMS Lifesciences India